Cost of tuberculosis in the era of multidrug resistance: Will it become unaffordable?

European Respiratory Journal

Volumn 40, Issue 1, 2012, Pages 9-11

  Loddenkemper, Robert ^a   Sotgiu, Giovanni ^b   Mitnick, Carole D ^c  

^a German Central Committee Against Tuberculosis   (Germany)

^b UNIVERSITY OF SASSARI   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; KANAMYCIN; LINEZOLID; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; EDITORIAL; EPIDEMIC; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INTEGRATED HEALTH CARE SYSTEM; LENGTH OF STAY; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; TREATMENT OUTCOME; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84863450231     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00027612     Document Type: Editorial

References (16)

1. Koch R. The Current State of the Struggle against Tuberculosis. www.nobelprize.org/nobel-prizes/medicine/laureates/1905/kochlecture.html
2. Dheda K, Migliori GB. The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? Lancet 2012; 379: 773-775.
3. Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet 2006; 367: 952-955.
4. World Health Organization. Global Tuberculosis Control Report 2011. Geneva, Switzerland, 2011.
5. World Health Organization. Consolidated action plan to prevent and combatmultidrug- and extensively drug-resistant tuberculosis in the WHO European Region 2011-2015. www.euro.who.int/-data/assets/pdf-file/0007/147832/wd15E-TB- ActionPlan-111388.pdf Date last updated: July 21, 2011.
6. Keshavjee S, Farmer P. Picking up the pace - scale up of MDR tuberculosis treatment programs. N Engl J Med 2010; 363: 1781-1784.
7. Trébucq A, Enarson DA, Chiang CY, et al. Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int J Tuberc Lung Dis 2011; 15: 1567-1572.
8. World Health Organization. 2011/2012 Tuberculosis Global Facts. Geneva, Switzerland, 2011.
9. Floyd K, Hutubessy R, Kliiman K, et al. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. Eur Respir J 2012; 40: 133-142.
10. Suárez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-1989. (Pubitemid 34663712)
11. Tupasi TE, Gupta R, Quelapio MID, et al. Feasibility and cost-effectiveness of treating multidrug resistant tuberculosis: a cohort study in the Philippines. PLoS Medicine 2006; 3: e352.
12. Rajbhandary SS, Marks SM, Bock NN. Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2004; 8: 1012-1016. (Pubitemid 39024906)
13. Diel R, Rutz S, Castell S, et al. Tuberculosis: cost of illness in Germany. Eur Respir J 2012; 40: 143-151.
14. Blaas SH, Mütterlein R, Weig J, et al. Extensively drug-resistant tuberculosis in a high-income country: a report of four unrelated cases. BMC Infect Dis 2008; 8: 60.
15. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
16. Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of multidrug-resistant tuberculosis. Pharmacoeconomics 2012; 30: 63-80.